D.E. Shaw & Co
NAVB

D.E. Shaw & Co’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

D.E. Shaw & Co’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-12,220
Closed -$154K – 3726
2016
Q4 		$154K Sell
12,220
-8,391
-41% -$133K ﹤0.01% 3309
2016
Q3 		$377K Sell
20,611
-3,889
-16% -$49.2K ﹤0.01% 2938
2016
Q2 		$260K Buy
24,500
+14,388
+142% +$283K ﹤0.01% 3089
2016
Q1 		$191K Buy
10,112
+4,940
+96% +$95.1K ﹤0.01% 3202
2015
Q4 		$138K Buy
+5,172
New +$180K ﹤0.01% 3636
2015
Q3 		– Sell
-1,313
Closed -$42K – 4016
2015
Q2 		$42K Buy
+1,313
New +$38.1K ﹤0.01% 3698
2015
Q1 		– Sell
-1,564
Closed -$59K – 4166
2014
Q4 		$59K Buy
+1,564
New +$43K ﹤0.01% 3932
2014
Q3 		– Sell
-552
Closed -$16K – 4539
2014
Q2 		$16K Buy
+552
New +$17.9K ﹤0.01% 4129
2013
Q4 		– Sell
-1,331
Closed -$71K – 4810
2013
Q3 		$71K Buy
+1,331
New +$77.6K ﹤0.01% 4215

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFS
Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

D.E. Shaw & Co's NAVB Position: Q1 2017 in Review

D.E. Shaw & Co sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q1 2017, closing a stake of 12,220 shares — an estimated $154K sold.

D.E. Shaw & Co first reported a position in NAVB in Q3 2013 and held it in 9 quarters. The position peaked at $377K in Q3 2016. 52 funds tracked by Wall St. Rank hold NAVB as of Q1 2017.

  • D.E. Shaw & Co reported no remaining Navidea Biopharmaceuticals Inc. position as of Q1 2017 after selling out during the quarter.
  • D.E. Shaw & Co sold 12,220 Navidea Biopharmaceuticals Inc. shares in Q1 2017, an estimated $154K.
  • D.E. Shaw & Co first reported a position in Navidea Biopharmaceuticals Inc. in Q3 2013 and held it in 9 quarters.
  • D.E. Shaw & Co's Navidea Biopharmaceuticals Inc. position peaked at $377K in Q3 2016.
  • 52 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q1 2017.

Based on D.E. Shaw & Co's 13F filing for Q1 2017, filed 15 May 2017.